GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (OSTO:BIOSGN) » Definitions » Total Tax Payable

Biosergen AB (OSTO:BIOSGN) Total Tax Payable : kr0.00 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB Total Tax Payable?

Biosergen AB's Total Tax Payable for the quarter that ended in Sep. 2024 was kr0.00 Mil.


Biosergen AB Total Tax Payable Historical Data

The historical data trend for Biosergen AB's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosergen AB Total Tax Payable Chart

Biosergen AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Tax Payable
- - - -

Biosergen AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biosergen AB Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.


Biosergen AB Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Biosergen AB's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosergen AB Business Description

Traded in Other Exchanges
N/A
Address
Fogdevreten 2, Solna, SWE, 17165
Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.

Biosergen AB Headlines

No Headlines